[1]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435-436.
 ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma: analysis of the prognosis and survival[J].journal interventional radiology,2014,(05):435-436.
点击复制

 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2014年05期
页码:
435-436
栏目:
临床研究
出版日期:
2014-05-28

文章信息/Info

Title:
 Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma: analysis of the prognosis and survival
作者:
 阿布都外力·吾布力卡斯穆 迪里木拉提·巴吾冬 任伟新
Author(s):
 ABUDUWAILI Obulikasimu DILMURAT Bawudun REN Wei- xin.
 Department of Interventional Radiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830054, China
关键词:
 【关键词】 肝细胞肝癌 肝动脉灌注化疗栓塞术 巴塞罗那临床肝癌分期 生存率
文献标志码:
A
摘要:
 【摘要】 目的 探讨肝动脉化疗栓塞(TACE)治疗巴塞罗那临床肝癌分期(BCLC) B期肝细胞肝癌(HCC)的预后及生存率。方法 对2007年2月—2013年1月行TACE治疗的BCLC B期HCC患者总共有197例进行回顾性分析,且所有病例通过住院及电话随访,根据患者临床资料进行预后及生存分析。结果 197例HCC患者中位随访时间为12(6 ~ 77)个月。中位生存期为24(2 ~ 77)个月。肝功能Child-Pugh A级患者生存率明显优于Child-Pugh B级患者(各为35个月和15个月,P < 0.01)。BCLC B1期患者生存率明显优于B2,B3和B4,中位生存期分别为35、25、9和7个月(P < 0.01)。不同年龄、性别、民族、肝炎病史以及甲胎蛋白水平之间无明显生存差异。结论 TACE治疗BCLC B期HCC患者可以明显提高其生存率,并且通过BCLC分期及肝功能Child-Pugh分级可以预测和评估患者TACE术后的预后及生存率。

参考文献/References:

[1] Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual[M]. Sixth Edition. Chicago, IL: Springer, 2002: 1 - 469.
[2] Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective?A systematic review of cohort and randomized studies[J].Cardiovasc Inter vent Radiol, 2007,30: 6 - 25.
[3] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology, 2003, 37: 429 - 442.
[4] Llovet JM, Re al MI, Montana X, et al. Arterial embolization or, chemoembolization versus systematic treatment in patients with, unresectable hepatocellular carcinoma: a randomised controlled Trail[J]. Lancet, 2002, 359: 1734 - 1739.
[5] Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate- stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization[J]. Cancer Treat Rev, 2011, 37: 212 - 20.
[6]Peck-Radosavljevic M, Sieghart W, Kölblinger C, et al. Austrian Joint ÖGGH-ÖG?R-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. Wien Clin Wochenschr 2012; 124: 104-10.
[7] Hsu CY, Lee YH, Hsia CY, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system[J]. Hepatology, 2013, 57: 112 - 119.
[8] Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study[J]. Ann Surg Oncol, 2011, 18: 413 - 420.
[9] Chung GE, Lee JH, Kim HY, et al. Transarterial chemoemboli- zation can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology, 2011, 258: 627 - 634.
[10] Kim KM, Kim JH, Park IS, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion[J]. J Gastroenterol Hepatol, 2009, 24: 806 - 814.
[11] Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommenda- tions on hepatocellular carcinoma[J]. Hepatol Int, 2010, 4: 439 - 474.
[12] Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus- based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version[J]. Dig Dis, 2011, 29: 339 - 364.
[13] Yoo DJ, Kim KM, Jin YJ, et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?[J]. J Gastroenterol Hepatol, 2011, 26: 145 - 154.
[14] 陈自谦, 杨 利, 杨熙章, 等. 肝癌介入治疗现状与进展[J]. 介入放射学杂志, 2008, 17: 223 - 227.
[15] Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: Clues for the best strategy[J]. Hepatology, 2000, 31: 1019 - 1021.
[16] Ilkay ID ILMAN, Bora PEYN IRCIO GLU, Barbaros Erhan ÇIL, et al. Transarterial chemoembolization for treatment of hepatocellular carcinoma: a single center experience[J]. Turk J Gastroenterol, 2013, 24: 141 - 147.
[17] 刘纪营, 金 洁, 管 生, 等. 肝功能状态对晚期肝癌介人治疗生存期的影响[J]. 介人放射学杂志, 2013, 22: 247 - 257.

相似文献/References:

[1]张 琳,黄学全,王健,等.自主研发电化学治疗同轴电极与传统针式电极电解效应的对比研究[J].介入放射学杂志,2012,(02):148.
 ZHANG Lin,HUANG Xue-quan,WANG Jian,et al.The electrolytic effect in electrochemotherapy: a comparative study between self-prepared coaxial electrode and conventional needle electrode[J].journal interventional radiology,2012,(05):148.
[2]赵 玮,王伟中,陈莹,等.耳部动静脉畸形供血动脉的血管造影研究[J].介入放射学杂志,2012,(02):103.
 ZHAO Wei,WANG Wei-zhong,CHEN Ying,et al.Angiographic findings of the feeding arteries of auricular arteriovenous malformations[J].journal interventional radiology,2012,(05):103.
[3]邹俊民,龙世娟,张振明. 改良髂内动脉化疗联合放疗治疗Ⅲ~Ⅳa期 子宫颈癌32例[J].介入放射学杂志,2012,(02):123.
 ZOU Jun-min,LONG Shi-Juan,ZHANG Zheng-ming..Improved internal iliac artery chemotherapy combined with radiotherapy for the treatment of stage Ⅲ-Ⅳa cervical cancers[J].journal interventional radiology,2012,(05):123.
[4]王昌明,李 选,宋世兵,等.肝门部胆道引流管折叠技术在肝移植后胆道非吻合口狭窄治疗中的应用[J].介入放射学杂志,2012,(02):136.
 WANG Chang-ming,LI Xuan,SONG Shi-bing,et al.The application of biliary catheter folding technique in the treatment of hilar nonanastomotic biliary strictures after orthotopic liver transplantation[J].journal interventional radiology,2012,(05):136.
[5]赵玉峰,孙玉琴,韩晓静,等. 输卵管介入再通术后受孕时机的研究[J].介入放射学杂志,2012,(02):158.
 ZHAO Yu-feng,SUN Yu-qin,HAN Xiao-jing,et al.The optimal time for conception after fallopian tube recanalization therapy[J].journal interventional radiology,2012,(05):158.
[6]含 笑,曹建民,史东宏,等.吉西他滨、顺铂动静脉联合化疗治疗晚期非小细胞肺癌的近期疗效分析[J].介入放射学杂志,2012,(02):119.
 HAN Xiao,CAO Jian-min,SHI Dong-hong,et al.Bronchial artery infusion of Gemcitabine and Cisplatin combined with systemic chemotherapy for advanced non-small cell lung cancer: its short-term efficacy[J].journal interventional radiology,2012,(05):119.
[7]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良RECIST标准更可靠[J].介入放射学杂志,2012,(03):177.
 . Therapeutic evaluation criterion of inoperable hepatocellular carcinomas: modified RECIST as a more reliable standard[J].journal interventional radiology,2012,(05):177.
[8]齐 立,李慎茂,俸军林,等. 动脉溶栓与机械碎栓联合动脉溶栓的对比分析[J].介入放射学杂志,2012,(03):180.
 ,,et al. Comparison of the therapeutic efficacy between simple arterial thrombolysis and mechanical thrombectomy combined with arterial thrombolysis for acute cerebral infarction at its ultraearly stage[J].journal interventional radiology,2012,(05):180.
[9]石 潆,赵 卫,沈 进,等.脑动静脉畸形栓塞治疗术并发颅内出血的原因及处理[J].介入放射学杂志,2012,(03):185.
 ,,et al.Intracranial hemorrhage due to embolization therapy for cerebral arteriovenous malformation: its causes and management [J].journal interventional radiology,2012,(05):185.
[10]周 慷,李晓光,金征宇,等.清宫术前子宫动脉化疗栓塞术治疗瘢痕妊娠的疗效分析[J].介入放射学杂志,2012,(03):190.
 ,,et al.Therapeutic analysis of bilateral uterine artery chemoembolization performed before uterine dilation and curettage for cesarean scar pregnancy [J].journal interventional radiology,2012,(05):190.
[11]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
 XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib: initial experience in 23 cases[J].journal interventional radiology,2014,(05):449.

备注/Memo

备注/Memo:
 (收稿日期:2013-11-28)
更新日期/Last Update: